Clinical Trial Update: Safety Study of Zinc Finger Nuclease CCR5-modified Hematopoietic Stem/Progenitor Cells in HIV-1 Infected Patients [Phase 1]

View source ↗

Summary

A Phase 1 safety study evaluating zinc finger nuclease-edited CCR5-modified hematopoietic stem/progenitor cells in HIV-1 infected patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Immunodeficiency Virus Infection

Drugs mentioned

• ZFN CCR5-modified hematopoietic stem/progenitor cells (zinc finger nuclease CCR5-modified hematopoietic stem/progenitor cells)

Snippet

Sponsor: City of Hope Medical Center | Conditions: HIV | Phase 1 | Status: ACTIVE_NOT_RECRUITING